Biocon Limited

Biocon Research Limited

Biocon Biologics Limited

Partha Hazra

Harish Iyer

Nitesh Dave

Sanjay Tiwari

Kedarnath Nanjund Sastry

Shrikumar Suryanarayan

Anand Khedkar

Anuj Goel

Mukesh Babuappa Patale

Gautam Krishnan

Goldy Sachdev

Nita Roy

Manjunath Hadavanahalli Shivarudraiah

Nagaraj Govindappa

Suma Sreenivas

Mayank Kumar Garg

Gokul Jothiraman

Krishnamurthy Venkatesan

Azimoddin Minyasab Shaikh

Sandhya Hedge

Ramprabu Nagarajan

Govindasamy Manikam

H S Manjunath

Nandini Nataraj

Minal Hashim

Anupama Jagadish

Anoop Vasudevan

Vivekanandan Kannan

Srikanth Gollarahosahalli Sathyanarayana

Srikanth G Sathyanarayan

Dinesh Channabasappa Goudar

Madhavan Buddha

Mayank Garg

The present invention relates to a process for purification of non-glycosylated insulin analogues 5 from a mixture comprising glycosylated and non-glycosylated proteins by removal of glycosylated proteins. The removal is achieved by combination of two RP-HPLC steps.

Chromatography process for purification of insulin analogues

The present invention relates to production of Human Insulin methyl ester by enzymatic reaction. The present invention further relates to production and enhancement of purity of Human Insulin Methyl ester.

Method of production of human insulin methyl ester

The present invention relates to the preparation of insulin compounds including their analogs or derivatives thereof from their corresponding precursor forms by a one step enzymatic reaction involving the combinatorial and concurrent use of optimal quantities of trypsin and carboxypeptidase B that work synergistically directing the reaction in a controlled manner to avoid production of random undesired byproducts. Particularly, the enzymatic conversion reactions of the instant invention offer advantages of reduction in the number operational steps, higher yield and purity of the desired end products.

Process for preparation of insulin compounds

The present invention relates to novel Prolipase-Bovine trypsinogen (PLBTR) fusion proteins, the genes encoding them, and the production and uses thereof. More specifically, the present invention relates to methods of producing in optimal quantities PLBTR fusion proteins which comprise a heterologous polypeptide which is normally susceptible to autocatalytic activity. More particularly, the present invention relates to fusion proteins which comprise an heterologous polypeptide, such as a serine protease, fused to a lipase signal sequence, which can be expressed by recombinant host cells in desired amounts. The present invention further relates to polynucleotides encoding such fusion proteins, to expression vectors for expression of such fusion proteins, to host cells transformed with such polynucleotides/vectors, and to methods of generating such fusion proteins.

Fusion proteins and method of expression thereof

The invention relates to methods of separation and/or purification of impurities yielding a purified heterologous protein product devoid of related impurities or with substantially minimal quantities of such glycosylated impurities. More specifically, the invention relates to the identification of glycosylated forms of insulin analogues such as glargine impurities characterized post expression in yeast based systems such as. The invention also relates to methods used to clone gene encoding the protein insulin glargine; inserting the related gene in a suitable yeast host; producing culture of the recombinant strain, stimulating expression of the heterologous polypeptide, its secretion and purification post fermentation and related enzymatic conversions.

Method of obtaining a purified, biologically active heterologous protein

The invention claims a process for making an insulin-oligomer conjugate IN-105. IN-105 precursor having formula G-A-V-R-[B-Chain]-R-D-A-D-D-R-[A-Chain] is cloned and expressed in. The biosynthetic precursor is then conjugated with an activated oligomer. The IN-105 precursor-oligomer conjugate is then treated with protease and purified to afford active insulin-oligomer conjugate of formula insulin-OC&#x2014;CH&#x2014;CH&#x2014;(OCHCH)&#x2014;OCH.

Process for the preparation of insulin conjugate IN-105

The present invention discloses a process for making an insulin-oligomer conjugate as a one-pot reaction by conjugation of insulin-ester with an activated oligomer wherein simultaneous deblocking and conjugation is carried out.

Preparation of insulin conjugates

Growing community of inventors

Karnataka, India

Partha Hazra